Find trials
Search tips

Dysgeusia Frequency of COVID-19 Patients Treated With Paxlovid Therapy in an Outpatient Primary Care Setting

Overview

About this study

The purpose of this study is to evaluate the frequency of dysgeusia in patients who took Paxlovid therapy as an outpatient for COVID-19 infection. Also, to evaluate the proportion of patients who discontinued Paxlovid therapy prematurely due to dysgeusia. Additionally, to identify risk factors for dysgeusia in patients on Paxlovid therapy, and to identify successful strategies for management of dysgeusia with Paxlovid.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients age 18 and older who were diagnosed with COVID-19 confirmed with a positive test and were prescribed a course of Paxlovid therapy.

Exclusion Criteria: 

  • Unable to complete survey.
  • Prior history of dysgeusia.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 1/4/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Jose Valery, M.D.

Open for enrollment

Contact information:

Jose Valery M.D.

(904) 953-6722

PaxlovidStudy@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20588154

Mayo Clinic Footer